Technical Analysis for RLMD - Relmada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Earnings Movers | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.26% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.26% | |
| Narrow Range Bar | Range Contraction | 0.26% | |
| Inside Day | Range Contraction | 0.26% | |
| Wide Bands | Range Expansion | 0.26% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -0.52% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.52% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 16 hours ago |
| Up 3% | about 16 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| Outside Day | about 17 hours ago |
| Up 2% | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.2225 |
| 52 Week Low | 2.3601 |
| Average Volume | 161,293 |
| 200-Day Moving Average | 3.72 |
| 50-Day Moving Average | 4.80 |
| 20-Day Moving Average | 4.01 |
| 10-Day Moving Average | 3.73 |
| Average True Range | 0.31 |
| RSI (14) | 40.83 |
| ADX | 34.51 |
| +DI | 15.11 |
| -DI | 23.92 |
| Chandelier Exit (Long, 3 ATRs) | 4.17 |
| Chandelier Exit (Short, 3 ATRs) | 4.27 |
| Upper Bollinger Bands | 4.76 |
| Lower Bollinger Band | 3.26 |
| Percent B (%b) | 0.38 |
| BandWidth | 37.30 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.31 |
| MACD Histogram | 0.0332 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.13 | ||||
| Resistance 3 (R3) | 4.14 | 4.04 | 4.08 | ||
| Resistance 2 (R2) | 4.04 | 3.97 | 4.04 | 4.06 | |
| Resistance 1 (R1) | 3.94 | 3.92 | 3.99 | 3.93 | 4.05 |
| Pivot Point | 3.84 | 3.84 | 3.87 | 3.84 | 3.84 |
| Support 1 (S1) | 3.74 | 3.77 | 3.79 | 3.73 | 3.61 |
| Support 2 (S2) | 3.64 | 3.72 | 3.64 | 3.60 | |
| Support 3 (S3) | 3.54 | 3.64 | 3.58 | ||
| Support 4 (S4) | 3.53 |
